PRVA — Privia Health Group, Inc.

Privia Health (PRVA) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Practice Collections: Increased by 27.1% year-over-year to $940.4 million.
• Adjusted EBITDA: Rose 61.6% to $38.2 million, with an EBITDA margin of 30.5%, reflecting a 720 basis point improvement.
• Total Attributed Lives: Grew approximately 13% year-over-year, expected to exceed 1.5 million with the acquisition of Evolent Health's ACO business.
• Pro Forma Cash: Ended Q3 with $409.9 million in cash and no debt.
• Year-to-Date Performance: Practice collections up 19.6% to $2.6 billion; adjusted EBITDA increased 43.5% to $94.1 million.

2. Strategic Updates and Business Highlights:

• Provider Growth: Implemented provider count increased by 13.1% year-over-year to 5,250.
• ACO Acquisition: Announced acquisition of an ACO from Evolent Health for $100 million, expected to close by year-end 2025, adding over 120,000 attributed lives.
• Value-Based Care Success: Strong performance in the Medicare Shared Savings Program (MSSP) with a savings rate of 9.4%, up from 8.2% in 2023, resulting in total shared savings of $234.1 million.
• Market Expansion: Continued entry into new markets, including Arizona, contributing to growth in attributed lives.

3. Forward Guidance and Outlook:

• 2025 Guidance Update: Raised expectations for implemented providers to grow by 11.2% and attributed lives by approximately 12.5%. Practice collections are expected to grow by 17.1%, and adjusted EBITDA by 32%.
• 2026 Outlook: Targeting adjusted EBITDA of approximately $130 million, with expectations for continued strong performance.

4. Bad News, Challenges, or Points of Concern:

• Cautious Q4 Expectations: While Q3 performance was strong, management indicated a conservative outlook for Q4, not providing specific quarterly guidance.
• Capitated Business Risks: Acknowledged ongoing headwinds in the Medicare Advantage (MA) environment, with a cautious approach to increasing risk in capitated contracts.
• Potential Margin Compression: Some analysts noted limited profitability growth expected in Q4, with concerns about potential margin compression.

5. Notable Q&A Insights:

• MSSP Performance: Management indicated that outperformance in MSSP will be factored into future guidance, maintaining a consistent approach to forecasting.
• Integration of Evolent Acquisition: Management emphasized the long-term nature of integrating the Evolent ACO and improving its performance over time.
• Payer Relationships: Continued strong relationships with payers are expected to yield incremental gains, with ongoing discussions about value-based care contracts.
• Utilization Trends: Management noted elevated utilization trends in ambulatory care, with expectations for continued strong performance in Q4, despite potential shifts in patient coverage.

Overall, Privia Health demonstrated robust financial performance in Q3 2025, with strategic initiatives aimed at expanding its value-based care model and enhancing its market presence. However, management remains cautious about the near-term outlook, particularly regarding Q4 performance and the broader MA landscape.